SNX8 is a direct interacting and repressor of FASN, a key rate-limiting enzyme in the de novo synthesis of fatty acids, which plays an important role in the pathogenesis of NAFLD (119). Here, FASN is linked to metabolic dysfunction-associated steatotic liver disease.